CT scan in August 2002 revealed a solitary metastatic lesion to the liver. An ultrasound of the abdomen confirmed 2 liver metastases, with the largest lesion in the left liver lobe measuring 3.1 × 3.7 × 3.2 centimeters; there was also a 1.2-centimeter lesion in the right liver lobe. Obstruction to the left-sided intrahepatic bile ducts with secondary mild dilatation of the ducts peripherally was also present.
In September 2002, his CEA increased to 18.7. In addition, his serum alkaline phosphatase and aspartate aminotransferase were elevated. The patient then underwent exploratory surgery with plans to resect the liver lesions and insert an intrahepatic chemotherapy pump. However, his disease was found to be unresectable because of a large, firm fixed mass in the area of the hilum outside of the liver. There was also metastatic carcinoma to the left portal lymph node, but 2 lymph nodes near the hepatic artery were not involved with tumor.
An MRI of the abdomen in October 2002 revealed 3 liver lesions, the largest in the left liver lobe measuring 3-4 centimeters and 2 smaller lesions in the right lobe.
October 2002-December 2002. Patient received 3 cycles of intravenous irinotecan (CPT-11 or Camptosar  ) along with capecitabine (Xeloda  ) 3500 milligrams for days 1-14, then 1 week off of chemotherapy. Patient tolerated Xeloda very poorly, with nausea and vomiting during cycles 2 and 3. The dose of Xeloda was decreased to 2000 mg for the third cycle; however, he continued to have severe vomiting.
MRI of abdomen from December 2002 revealed resolution of all 3 hepatic lesions and no new metastasis.
In December 2002, patient presented to Block Center for Integrative Cancer Care for continuation of his treatment with an integrative program with the expectation of decreasing the toxicity of chemotherapy.
Past medical history: Not significant.
Past surgical history: Appendectomy as a teenager. His last colonoscopy was in September 2002.
Family history: Father is 74 years old with a history of colon cancer diagnosed at the age of 67, he is status postsurgery, adjuvant chemotherapy, and liver tumor resection. His mother is 72, alive and well. He has 3 sisters and 1 brother between the ages of 35 and 54 who are alive and in good health. He has 3 children, ages 13, 22, and 32, who are alive and well. 
Traditional Chinese Medicine Symptoms and Signs
Systemic: Feels cold after chemotherapy (fine after a week); runs out of energy by dinnertime; complains of dry skin. Intake: Appetite fine; weight stable; thirst normal.
Outflow: Looser excrement and undigested food particles in colostomy bag during chemo time (returns to normal after a week).
Sleep:
Sleeps fine from about 10 PM to 6 AM.
Behavior: Talkative and outgoing.
Tongue tissue: Very pale, slightly purple hue, swollen around edges, turns downward upon extension.
Tongue coating: None around edges, greasy and white in middle to root. 
Medical Oncology
In 2002, colorectal cancer was the third most commonly diagnosed cancer in both men and women. Slightly more than 100,000 new cases of colorectal cancer are diagnosed per year and about 48,000 people die of the disease per year. During the past 3 decades, mortality from the disease has decreased as a testament to early diagnosis and better treatment modalities. This case highlights many aspects in the care and management of patients with colorectal cancer. The case deals with the management of nonmetastatic rectal cancer, follow-up recommendations for patients previously diagnosed and treated, and management of stage IV colorectal cancer.
At initial presentation in 1997, the patient noted hematochezia and underwent a complete staging workup that included a total colonoscopy with pathological tissue review, blood work, and imaging studies. The patient underwent a low anterior resection and was diagnosed as having a stage III, T1N1M0 rectal cancer. Such patients are at risk for both distant recurrences, typically in the liver, and local pelvic recurrence, which carries significant morbidity. For stage III disease with no postoperative or adjuvant therapy, both the distant and local failure rates are in the range of 50%. In 1990, a Consensus Development Conference sponsored by the National Institute of Health concluded that adjuvant therapy consisting of the combination of chemotherapy and radiation should become the standard in both stage II and stage III rectal cancers. 1 In cases such as this, where cancers are located very low near the sphincter, maintenance of continence is a common difficulty encountered and is most certainly aggravated by irradiation. However, using external beam therapy with 5000 to 5400 cGy, the local failure rate is halved. Of late there has been some debate that better surgical techniques using a total mesorectal excision, where there is sharp dissection around the integral mesentery of the hindgut, will decrease local failure rates and avoid the need for adjuvant radiation. This technique has not withstood the rigors of a prospective randomized multi-institutional trial.
Three clinical trials conducted in the 1980s showed a survival advantage for stages II and III rectal cancers where 5-fluorouracil (5-FU) was given concomitantly with the radiation. These trials conducted by the National Surgical and Adjuvant Breast Project, 2 the North Central Cancer Tumor Group, 3 and the GI Tumor Study Group 4 showed 5-FU-based chemotherapy with pelvic irradiation improved 5-year survival on average from 45% to 60%. The best method of delivery of the 5-FU is debated, but in general it is either given as a low-dose continuous infusion (200-250 mg/ m2/day) during the irradiation or as quicker infusions during the first and fifth weeks of irradiation. Additionally, 4 more months of 5-FU-based therapy are given to reach a total of 6 treatments. Again, how best to deliver the 5-FU is not clear, but as Moore and Haller 5 reviewed in their data, the standard has become the use of 5-FU and leucovorin for 6 months
